Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02946489 · ClinicalTrials.gov registry record · Phase 1
Facilitating the Behavioral Treatment of Cannabis Use Disorder
A Phase 1 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02946489 is a Phase 1 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 8 participants.
The verdict
NCT02946489, a Phase 1 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
Cannabis use disorders remain a significant public health problem. The pharmacological facilitation of behavioral treatment represents a promising strategy for addressing disordered cannabis use. Cannabis use disorders are recognized to be associated with various vulnerabilities that complicate the course of treatment and that may be amenable to glutamate modulators. The purpose of this single blind open-label trial is to test the feasibility of administering glutamate modulators in conjunction with motivational enhancement therapy (MET) and mindfulness based relapse prevention (MBRP) for cannabis use disorders.
Interventions
- DRUG CI-581a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2016-10 |
| Est. Completion | 2018-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02946489
The ClinicalTrials.gov registry entry for NCT02946489 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CI-581a is the first listed.
NCT02946489 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02946489 about?
NCT02946489 is a clinical study titled "Facilitating the Behavioral Treatment of Cannabis Use Disorder". Cannabis use disorders remain a significant public health problem. The pharmacological facilitation of behavioral treatment represents a promising strategy for addressing disordered cannabis use. Cannabis use disorders are recognized to be associated with various vulnerabilities that complicate the ...
What is the current status of trial NCT02946489?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2016-10. Estimated completion is 2018-08.
What interventions are being tested in trial NCT02946489?
The interventions under investigation include: CI-581a (DRUG).
Who is sponsoring clinical trial NCT02946489?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.